title: Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study.
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: B K
authors: BK
authors: Hamilton
authors: Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.
authors: L
authors: L
authors: Rybicki
authors: Department of Hematology/Oncology, Staten Island University Hospital, New York, NY, USA.
authors: H
authors: H
authors: Haddad
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: D
authors: D
authors: Abounader
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: M
authors: M
authors: Yurch
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: N S
authors: NS
authors: Majhail
authors: Department of Pediatric Hematology & Oncology, Cleveland Clinic, Cleveland, OH, USA.
authors: R
authors: R
authors: Hanna
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: R
authors: R
authors: Sobecks
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: R
authors: R
authors: Dean
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: H
authors: H
authors: Liu
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: B
authors: B
authors: Hill
authors: Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
authors: E
authors: E
authors: Copelan
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: B
authors: B
authors: Bolwell
authors: Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors: M
authors: M
authors: Kalaycio
mesh_terms: D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D008727:Methotrexate